Arimidex is a hormonal antitumor agent, the therapeutic effect of which is due to the properties of the active component-anastrozole. It is prescribed for women with breast tumors. Due to the therapy, there is a significant decrease in the level of estradiol. The drug has a good pharmacological profile – anastrozole is completely absorbed in the gastrointestinal tract, quickly creating a therapeutic concentration. Progestogenic, estrogenic and androgenic activity of the drug does not show. The use of Arimidex in pediatrics is contraindicated. Take the drug in the presence of confirmed hypersensitivity to the components, against the background of severe violations of liver and kidney function can not be. Arimidex is prescribed in a standard dose (including elderly women) - 1 mg per day. The duration of therapy is determined by the progression of symptoms and tolerability. Side effects that occur against the background of taking the drug, usually manifest themselves easily and are reversible. Most often, women reported asthenia, arthritis, digestive disorders, vaginal bleeding, hypercholesterolemia, bone pain, allergic reactions, and drowsiness.
It is an aromatase hormone antagonist. During the postmenopausal period, estradiol is produced by converting androstenedione to estrone in peripheral tissues under the action of the aromatase enzyme. Next, estrone is converted to estradiol. The active substance of the drug blocks this process. This reduces the level of estradiol, which is necessary in the treatment of breast cancer. In postmenopausal women, the drug at a dose of 1 mg/day causes a decrease in the level of estradiol by 80%. It has no progestogenic or androgenic activity; at a dose of up to 10 mg / day, it does not affect the secretion of aldosterone and cortisol.
- Active ingredient: Anastrozole (1 mg).
- Arimidex is available in the form of tablets.
Arimidex is used to treat advanced breast cancer in postmenopausal women (with positive indicators of hormone receptors).
Arimidex is not used:
Arimidex is used orally.
The recommended dose is 1 mg (one tablet) once a day.
In the early stages of invasive breast cancer (with positive hormone receptor values) in postmenopausal patients, the standard duration of adjuvant endocrine therapy is five years.
Patients with mild / moderate renal dysfunction do not need a dose adjustment. The use of the drug in this group of patients requires caution.
Patients with mild / moderate liver dysfunction do not need a dose adjustment. The use of the drug in this group of patients requires caution.
Use during pregnancy and lactation - Forbidden.
In animal studies, the drug has demonstrated low toxicity. Possible increase in adverse reactions.
In case of overdose, symptomatic, supportive therapy is performed. It is necessary to monitor vital signs, carefully monitor the patient. Dialysis may be performed.
Digestive disorders: Anorexia, hypercholesterolemia, hypercalcemia, nausea, diarrhea.
Hepatobiliary disorders: Hepatitis, increased levels of alkaline phosphatase, AsAT, AlAT, gamma-glutamyltransferase, bilirubin.
Neurological disorders: Headache, carpal tunnel syndrome, drowsiness, sensitivity disorders (paresthesia, loss of taste, changes in taste sensations).
Cardiovascular disorders: Hot flashes.
Allergic reactions: Allergic reactions (chills, chest pain, trembling, urticaria, skin rash), anaphylaxis (manifested by shortness of breath, hypotension, cardiac arrest), dermatitis.
Dermatological disorders: Exanthema, hair thinning, alopecia, erythema polymorph, cutaneous vasculitis, Schenlein-Henoch purpura, Stevens — Johnson syndrome.
Musculoskeletal disorders: Arthralgia, arthritis, impaired joint mobility, osteoporosis, bone pain, myalgia, snapping finger syndrome.
Urogenital disorders: Vaginal bleeding, vaginal dryness.
Arimidex must be stored in its original packaging in a place protected from direct sunlight, moisture, for no more than 5 years.
It is forbidden to use after the expiration date indicated on the package.
Recommended storage temperature: up to +30 °C.
Parents are obliged to ensure the safety of their children, excluding the possibility of their access to the medicine.